A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial

Your email address will not be published. Required fields are marked *

Name  *

Email  *

Website

Add Comment *

Save my name, email, and website in this browser for the next time I comment.

Subscribe to our email updates as well.

Post Comment